Back to News
Market Impact: 0.2
GRAIL Reaches Analyst Target Price
Source: Nasdaq
Analyst EstimatesMarket Technicals & FlowsHealthcare & Biotech
GRAIL shares rose above the average 12-month analyst price target of $76.00, trading at $79.95 per share. The move signals positive recent price momentum but also raises the prospect that analysts could reassess valuation or increase their targets.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
GRAL0.20
More News
- Stocks face a key hurdle in next week’s U.S.-China summit. Here’s what’s at stake
- Tokenization is set to change stock trading. These stocks could get a boost
- FTSE 100 today: Stocks drop as Hormuz tanker hit, Aramco cuts Europe supply
- Bank of Japan Hikes Interest Rates in a Split Vote; Yen Drops
- Buffett Steps Down at Berkshire
- European stocks snap two-week slide as Fed resolve
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Automating Financial Model Updates: A Source-Controlled Workflow
- Weekly Update: Live Event Center, In-App Documents, and Faster Transcripts